Stay updated on IMP321 Enhancing Anti-PD-1 in Melanoma Clinical Trial

Sign up to get notified when there's something new on the IMP321 Enhancing Anti-PD-1 in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IMP321 Enhancing Anti-PD-1 in Melanoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0.
    Difference
    0.1%
    Check dated 2026-11-01T17:13:02.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    A site-wide NIH notice about the terminology transition from “Artificial Intelligence” to “Super Intelligence” appears above the clinical trial record.
    Difference
    0.7%
    Check dated 2026-10-25T18:15:56.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The site footer now displays software revision v3.7.2 instead of v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-18T22:34:38.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov site revision changed from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-11T22:37:00.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    A new revision entry labeled v3.7.0 has been added to the study record history, representing the latest update to the record. The previous revision v3.6.6 has been removed from the list.
    Difference
    0.1%
    Check dated 2026-09-20T20:46:10.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    New latest revision entry v3.6.6 has been added to the Study Record History, replacing the prior v3.6.5. This documents an updated revision of the record on ClinicalTrials.gov.
    Difference
    0.1%
    Check dated 2026-08-30T21:49:26.000Z thumbnail image

Stay in the know with updates to IMP321 Enhancing Anti-PD-1 in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IMP321 Enhancing Anti-PD-1 in Melanoma Clinical Trial page.